Clinical Trial Update: A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy trial of Squalamine lactate for injection (MSI-1256F) for wet age-related macular degeneration has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Squalamine lactate for injection (MSI-1256F) (Squalamine lactate)

Snippet

Sponsor: Genaera Corporation | Conditions: "Wet" Age-Related Macular Degeneration | Phase 3 | Status: TERMINATED